Status:
COMPLETED
Microcirculation Properties of Albumin for Fluid Resuscitation in Septic Shock
Lead Sponsor:
Rachael Cusack
Collaborating Sponsors:
Grifols Biologicals, LLC
Conditions:
Sepsis, Severe
Sepsis
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The sublingual microcirculation is impaired in sepsis and septic shock. Sidestream dark field imaging technology has been developed into a clinical tool to help the clinician assess the microcirculati...
Detailed Description
Sepsis and septic shock are diseases of the microcirculation. Recent developments in microcirculation imaging have illustrated the extent of the impairment of the microcirculation in these diseases of...
Eligibility Criteria
Inclusion
- Sepsis; suspected source of infection, tachycardia, tachypneic, hyperlactatemia, hypotensive requiring vasopressors, febrile \>38.5degrees Celsius
- Fluid responsive; pulse pressure variability \>10% or passive leg raise positive
Exclusion
- Fluid overloaded; pulmonary oedema, significant peripheral oedema
- Heart Failure, cardiogenic shock, recent MI
- Receiving regular albumin 20%
Key Trial Info
Start Date :
September 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05357339
Start Date
September 1 2021
End Date
December 1 2023
Last Update
October 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St James's Hospital
Dublin, Dublin, Ireland, D03 WK19